Posterior Segment Company Showcase - Opthea at OIS@AAO 2016.
Presenter:
Megan Baldwin, PhD, CEO & Managing Director
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
RETINA COMPANY SHOWCASE- Ocular TherapeutixHealthegy
Presentation by Ocular Therapeutix at OIS@ASRS 2016.
Participant:
Jonathan Talamo, MD, Chief Medical Officer- Ocular Therapeutix
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Public Device & Biopharma Ophthalmology Company Showcase - Aerie PharmaceuticalsHealthegy
Public Device & Biopharma Ophthalmology Company Showcase - Aerie Pharmaceuticals at OIS@AAO 2016.
Presenter:
Vicente Anido Jr., PhD, CEO & Chairman
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Public Device & Biopharma Ophthalmology Company Showcase - Adverum Biotechnol...Healthegy
Public Device & Biopharma Ophthalmology Company Showcase - Adverum Biotechnologies at OIS@AAO 2016.
Presenter:
Samuel B. Barone, MD SVP, Clinical Development
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Posterior Segment Company Showcase - Clearside BiomedicalHealthegy
Posterior Segment Company Showcase - Clearside Biomedical at OIS@AAO 2016.
Presenter:
Daniel White, President & CEO
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Public Device & Biopharma Ophthalmology Company Showcase - QLTHealthegy
Public Device & Biopharma Ophthalmology Company Showcase - QLT at OIS@AAO 2016.
Presenter:
David Saperstein, MD, Chief Medical Advisor
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Posterior Segment Company Showcase - Ocular TherapeutixHealthegy
Posterior Segment Company Showcase - Ocular Therapeutix at OIS@AAO 2016.
Presenter:
Amar Sawhney, PhD, President, CEO & Chairman
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Public Device & Biopharma Ophthalmology Company Showcase - Inotek Pharmaceuti...Healthegy
Public Device & Biopharma Ophthalmology Company Showcase - Inotek Pharmaceuticals at OIS@AAO 2016.
Presenter:
David Southwell, President & CEO
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
RETINA COMPANY SHOWCASE- Ocular TherapeutixHealthegy
Presentation by Ocular Therapeutix at OIS@ASRS 2016.
Participant:
Jonathan Talamo, MD, Chief Medical Officer- Ocular Therapeutix
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Public Device & Biopharma Ophthalmology Company Showcase - Aerie PharmaceuticalsHealthegy
Public Device & Biopharma Ophthalmology Company Showcase - Aerie Pharmaceuticals at OIS@AAO 2016.
Presenter:
Vicente Anido Jr., PhD, CEO & Chairman
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Public Device & Biopharma Ophthalmology Company Showcase - Adverum Biotechnol...Healthegy
Public Device & Biopharma Ophthalmology Company Showcase - Adverum Biotechnologies at OIS@AAO 2016.
Presenter:
Samuel B. Barone, MD SVP, Clinical Development
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Posterior Segment Company Showcase - Clearside BiomedicalHealthegy
Posterior Segment Company Showcase - Clearside Biomedical at OIS@AAO 2016.
Presenter:
Daniel White, President & CEO
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Public Device & Biopharma Ophthalmology Company Showcase - QLTHealthegy
Public Device & Biopharma Ophthalmology Company Showcase - QLT at OIS@AAO 2016.
Presenter:
David Saperstein, MD, Chief Medical Advisor
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Posterior Segment Company Showcase - Ocular TherapeutixHealthegy
Posterior Segment Company Showcase - Ocular Therapeutix at OIS@AAO 2016.
Presenter:
Amar Sawhney, PhD, President, CEO & Chairman
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Public Device & Biopharma Ophthalmology Company Showcase - Inotek Pharmaceuti...Healthegy
Public Device & Biopharma Ophthalmology Company Showcase - Inotek Pharmaceuticals at OIS@AAO 2016.
Presenter:
David Southwell, President & CEO
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Posterior Segment Company Showcase - Aura BiosciencesHealthegy
Posterior Segment Company Showcase - Aura Biosciences at OIS@AAO 2016.
Presenter:
Elisabet de los Pinos, CEO
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Posterior Segment Company Showcase - Notal visionHealthegy
Posterior Segment Company Showcase - Notal vision at OIS@AAO 2016.
Presenter:
Quinton Oswald, CEO
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Posterior Segment Company Showcase - Ohr pharmaceuticalHealthegy
Posterior Segment Company Showcase - Ohr pharmaceutical at OIS@AAO 2016.
Presenter:
Jason Slakter, CEO
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Public Device & Biopharma Ophthalmology Company Showcase - OmerosHealthegy
Public Device & Biopharma Ophthalmology Company Showcase - Omeros at OIS@AAO 2016.
Presenter:
Leonard M. Blum, Chief Business & Commercial Officer
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Posterior Segment Company Showcase - PanOpticaHealthegy
Posterior Segment Company Showcase - PanOptica at OIS@AAO 2016.
Presenter:
Paul Chaney, Co-Founder, President & CEO
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Posterior Segment Company Showcase - Graybug VisionHealthegy
Posterior Segment Company Showcase - Graybug Vision at OIS@AAO 2016.
Presenter:
Jeffrey Cleland, PhD, President & CEO
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Public Device & Biopharma Ophthalmology Company Showcase - pSividaHealthegy
Public Device & Biopharma Ophthalmology Company Showcase - pSivida at OIS@AAO 2016.
Presenter:
Nancy Lurker, President & CEO
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Presentation from OIS@ASCRS 2016
Amar Sawhney, PhD, President, CEO & Chairman
Video Presentation:
https://www.youtube.com/watch?v=nGQzo6czij0&list=PL1dmdBNnPTZJBhQxPOp0vdNg3s3wtN2yw&index=31
Anterior Segment Company Showcase - AvedroHealthegy
Anterior Segment Company Showcase - Avedro at OIS@AAO 2016.
Presenter:
Rajesh K. Rajpal, MD, Chief Medical Officer
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Posterior Segment Company Showcase - AerpioHealthegy
Posterior Segment Company Showcase - Aerpio at OIS@AAO 2016.
Presenter:
Joseph Gardner, President & CEO
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Ophthalmic Innovation 2016 - "A View From The NEI"Healthegy
Ophthalmic Innovation 2016 - "A View From The NEI"
Presenter:
Mala Dutta, PhD, Lead, Office of Translational Research, National Eye Institute
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Posterior Segment Company Showcase - Allegro OphthalmicsHealthegy
Posterior Segment Company Showcase - Allegro Ophthalmics at OIS@AAO 2016.
Presenter:
Vicken Karageozian, MD, President & Chief Medical Officer
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Posterior Segment Company Showcase - Aura BiosciencesHealthegy
Posterior Segment Company Showcase - Aura Biosciences at OIS@AAO 2016.
Presenter:
Elisabet de los Pinos, CEO
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Posterior Segment Company Showcase - Notal visionHealthegy
Posterior Segment Company Showcase - Notal vision at OIS@AAO 2016.
Presenter:
Quinton Oswald, CEO
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Posterior Segment Company Showcase - Ohr pharmaceuticalHealthegy
Posterior Segment Company Showcase - Ohr pharmaceutical at OIS@AAO 2016.
Presenter:
Jason Slakter, CEO
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Public Device & Biopharma Ophthalmology Company Showcase - OmerosHealthegy
Public Device & Biopharma Ophthalmology Company Showcase - Omeros at OIS@AAO 2016.
Presenter:
Leonard M. Blum, Chief Business & Commercial Officer
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Posterior Segment Company Showcase - PanOpticaHealthegy
Posterior Segment Company Showcase - PanOptica at OIS@AAO 2016.
Presenter:
Paul Chaney, Co-Founder, President & CEO
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Posterior Segment Company Showcase - Graybug VisionHealthegy
Posterior Segment Company Showcase - Graybug Vision at OIS@AAO 2016.
Presenter:
Jeffrey Cleland, PhD, President & CEO
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Public Device & Biopharma Ophthalmology Company Showcase - pSividaHealthegy
Public Device & Biopharma Ophthalmology Company Showcase - pSivida at OIS@AAO 2016.
Presenter:
Nancy Lurker, President & CEO
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Presentation from OIS@ASCRS 2016
Amar Sawhney, PhD, President, CEO & Chairman
Video Presentation:
https://www.youtube.com/watch?v=nGQzo6czij0&list=PL1dmdBNnPTZJBhQxPOp0vdNg3s3wtN2yw&index=31
Anterior Segment Company Showcase - AvedroHealthegy
Anterior Segment Company Showcase - Avedro at OIS@AAO 2016.
Presenter:
Rajesh K. Rajpal, MD, Chief Medical Officer
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Posterior Segment Company Showcase - AerpioHealthegy
Posterior Segment Company Showcase - Aerpio at OIS@AAO 2016.
Presenter:
Joseph Gardner, President & CEO
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Ophthalmic Innovation 2016 - "A View From The NEI"Healthegy
Ophthalmic Innovation 2016 - "A View From The NEI"
Presenter:
Mala Dutta, PhD, Lead, Office of Translational Research, National Eye Institute
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Posterior Segment Company Showcase - Allegro OphthalmicsHealthegy
Posterior Segment Company Showcase - Allegro Ophthalmics at OIS@AAO 2016.
Presenter:
Vicken Karageozian, MD, President & Chief Medical Officer
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Posterior Segment Company Showcase - AGTCHealthegy
Posterior Segment Company Showcase - AGTC at OIS@AAO 2016.
Presenter:
Sue Washer, President & CEO
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Posterior Segment Company Showcase - Apellis PharmaceuticalsHealthegy
Posterior Segment Company Showcase - Apellis Pharmaceuticals at OIS@AAO 2016.
Presenter:
Cedric Francois, MD, PhD, CEO
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Masters of the Industry at OIS@AAO 2016.
Moderated By:
Jim Mazzo, Global President Ophthalmic Devices - Carl Zeiss Meditec
Participants:
Flemming Ornskov, MD, CEO - Shire
Mike Ball, CEO - Alcon
Ashley McEvoy, Company Group Chairman - Johnson & Johnson Vision Care
William J. Link, PhD, Managing Director - Versant Ventures
Ludwin Monz, PhD, President & CEO - Carl Zeiss Meditec
William Meury, Chief Commercial Officer - Allergan
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Posterior Segment Company Showcase - Alimera SciencesHealthegy
Posterior Segment Company Showcase - Alimera Sciences at OIS@AAO 2016.
Presenter:
Dan Myers, CEO
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
EMERGING APPROACHES TO COMBINATION THERAPIES IN AMD & DME - OptheaHealthegy
Panel Discussion by Opthea at OIS@ASRS 2016.
Participant:
Megan Baldwin, PhD, CEO & Managing Director - Opthea
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Here is the updated list of Top Best Ayurvedic medicine for Gas and Indigestion and those are Gas-O-Go Syp for Dyspepsia | Lavizyme Syrup for Acidity | Yumzyme Hepatoprotective Capsules etc
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
Basavarajeeyam is an important text for ayurvedic physician belonging to andhra pradehs. It is a popular compendium in various parts of our country as well as in andhra pradesh. The content of the text was presented in sanskrit and telugu language (Bilingual). One of the most famous book in ayurvedic pharmaceutics and therapeutics. This book contains 25 chapters called as prakaranas. Many rasaoushadis were explained, pioneer of dhatu druti, nadi pareeksha, mutra pareeksha etc. Belongs to the period of 15-16 century. New diseases like upadamsha, phiranga rogas are explained.
ABDOMINAL TRAUMA in pediatrics part one.drhasanrajab
Abdominal trauma in pediatrics refers to injuries or damage to the abdominal organs in children. It can occur due to various causes such as falls, motor vehicle accidents, sports-related injuries, and physical abuse. Children are more vulnerable to abdominal trauma due to their unique anatomical and physiological characteristics. Signs and symptoms include abdominal pain, tenderness, distension, vomiting, and signs of shock. Diagnosis involves physical examination, imaging studies, and laboratory tests. Management depends on the severity and may involve conservative treatment or surgical intervention. Prevention is crucial in reducing the incidence of abdominal trauma in children.
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Oleg Kshivets
Overall life span (LS) was 1671.7±1721.6 days and cumulative 5YS reached 62.4%, 10 years – 50.4%, 20 years – 44.6%. 94 LCP lived more than 5 years without cancer (LS=2958.6±1723.6 days), 22 – more than 10 years (LS=5571±1841.8 days). 67 LCP died because of LC (LS=471.9±344 days). AT significantly improved 5YS (68% vs. 53.7%) (P=0.028 by log-rank test). Cox modeling displayed that 5YS of LCP significantly depended on: N0-N12, T3-4, blood cell circuit, cell ratio factors (ratio between cancer cells-CC and blood cells subpopulations), LC cell dynamics, recalcification time, heparin tolerance, prothrombin index, protein, AT, procedure type (P=0.000-0.031). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and N0-12 (rank=1), thrombocytes/CC (rank=2), segmented neutrophils/CC (3), eosinophils/CC (4), erythrocytes/CC (5), healthy cells/CC (6), lymphocytes/CC (7), stick neutrophils/CC (8), leucocytes/CC (9), monocytes/CC (10). Correct prediction of 5YS was 100% by neural networks computing (error=0.000; area under ROC curve=1.0).
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
Rasamanikya is a excellent preparation in the field of Rasashastra, it is used in various Kushtha Roga, Shwasa, Vicharchika, Bhagandara, Vatarakta, and Phiranga Roga. In this article Preparation& Comparative analytical profile for both Formulationon i.e Rasamanikya prepared by Kushmanda swarasa & Churnodhaka Shodita Haratala. The study aims to provide insights into the comparative efficacy and analytical aspects of these formulations for enhanced therapeutic outcomes.
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
1. OPT-302:
A novel therapy for
Wet AMD
Ophthalmology Innovation Summit, October 13 2016
Megan Baldwin, CEO & Managing Director
2. Investment in Opthea Limited (‘Opthea’) is subject to investment risk, including possible loss of income and
capital invested. Neither Opthea nor any other member company of the Opthea Group guarantees any
particular rate of return or performance, nor do they guarantee the repayment of capital.
This presentation is not an offer or invitation for subscription or purchase of or a recommendation of
securities. It does not take into account the investment objectives, financial situation and particular needs of
the investor. Before making any investment in Opthea, the investor or prospective investor should consider
whether such an investment is appropriate to their particular investment needs, objectives and financial
circumstances and consult an investment advisor if necessary.
This presentation may contain forward-looking statements regarding the potential of the Company’s projects
and interests and the development and therapeutic potential of the company’s research and development.
Any statement describing a goal, expectation, intention or belief of the company is a forward-looking
statement and should be considered an at-risk statement. Such statements are subject to certain risks and
uncertainties, particularly those inherent in the process of discovering, developing and commercialising drugs
that are safe and effective for use as human therapeutics and the financing of such activities. There is no
guarantee that the Company’s research and development projects and interests (where applicable) will receive
regulatory approvals or prove to be commercially successful in the future. Actual results of further research
could differ from those projected or detailed in this presentation. As a result, you are cautioned not to rely on
forward-looking statements. Consideration should be given to these and other risks concerning research and
development programs referred to in this presentation.
2
Disclaimer
3. 3
Opthea: Developing OPT-302 for Wet AMD
• Opthea Limited is a public ASX listed
company (ASX: OPT)
• Exclusive worldwide rights to extensive
IP portfolio around members of the
Vascular Endothelial Growth Factor
family
• VEGF-C
• VEGF-D
• VEGFR-3
Key Financial Details ASX: OPT
Ticker Symbol ASX:OPT
Share Price (as at Aug 5 2016) ~A$0.73
Total Ordinary Shares on Issue 150,205,903
Options on Issue 49,707,097
Market Capitalisation
(as at Aug 5 2016)
~USD 84m
(AUD 110m)
• Lead compound OPT-302: a VEGF-C/-D ‘Trap’
• Neovascular effects (eg. inhibitor of angiogenesis & vascular permeability)
• Non-neovascular effects (eg. inflammation)
• Wet AMD program with potential in a range of eye diseases
• Combination therapy OPT-302 with an anti-VEGF-A inhibitor targets
mechanisms of incomplete response to VEGF-A inhibition
• Complementary to a-VEGF-A and other agents in development
• Phase 1/2a trial ongoing under IND at 14 clinical sites in US
4. 4
• Long-term single-agent therapy with
VEGF-A inhibitors is associated with
sub-optimal response
Sub-optimal improvements in visual
acuity (<15-letter gain)
Persistent retinal fluid
• Resistance to VEGF-A inhibitors may be
related to other VEGF family members
Resistance to anti-VEGF-A Monotherapy
EyleaTM LucentisTM OPT-302
VEGF-B
PIGF VEGF-A
VEGF-C
VEGF-D
• OPT-302 combination therapy achieves
more complete suppression of the
VEGF/VEGFR pathway
• Targets incomplete response to VEGF-A
inhibition
6. 6
OPT-302 Phase 1: Patient Demographics
• Run under FDA IND at 14 clinical sites in the US
• 20 pts (mean age 74.8)
• 14/20 females, 6/20 males
• 17/20 occult, 2/20 min classic, 1/20 predominantly classic
• Each patient received 3 intravitreal injections of OPT-302 either alone or in
combination with Lucentis ® every 4 weeks, with a week 12 follow-up one month
after the third dose.
• 70% difficult to treat patients sub-responsive to anti-VEGF-A therapy
• 30% treatment-naïve
Cohort Treatment # Naïve Pts # Prior
Treated Pts
1 OPT-302 (0.3 mg) + Lucentis® (0.5 mg) 2 3
2 OPT-302 (1.0 mg) + Lucentis® (0.5 mg) 0 5
3 OPT-302 (2.0 mg) + Lucentis® (0.5 mg) 2 3*
4 OPT-302 (2.0 mg) 2 3
*One pt with metastatic ovarian cancer died prior to the week 12 (day 78) visit due to
intercurrent illness unrelated to study drugs.
7. • OPT-302 successfully met primary safety objective in Phase 1 dose escalation study
• No dose limiting toxicities (and MTD not reached) through week 12 in:
• OPT-302 monotherapy (2.0 mg), and
• Cohorts of OPT-302 (0.3, 1, 2 mg) in combination with Lucentis® (0.5 mg)
• No signs of infection (endophthalmitis)
• No clinically significant changes in:
• Intraocular pressure
• ECGs
• Blood pressure
• Blood chemistry or other vital signs
• No evidence of drug-related immunogenicity
7
OPT-302 Safe & Well Tolerated in Phase 1 Study
8. 8
Phase 1 Secondary Endpoints
• Overall, 16/19 evaluable pts maintained or gained vision from
baseline to week 12
• No patient lost more than 3 letters. All of the patients that
lost VA from baseline received combination OPT-302 +
Lucentis® therapy.
9. 9
Combination Therapy: All Patients (Full cohort) (Naïve & Prior-Tx)
0
1
2
3
4
5
6
7
8
9
10
OPT-302 + Lucentis
(n=14*)
Mean VA gain from
baseline at Week 12
MeangaininVA
fromBaseline(#letters)
8 Letters
MeanCST(µM)
250
275
300
325
350
375
400
425
450
Baseline Week 12
Mean decrease in CST from
baseline to Week 12
OPT-302 + Lucentis
(n=14*)
-91µM
* 1 pt not evaluable at W12
10. 10
Combination Therapy: Treatment-Naïve Patients
16.5
9.5
0
2
4
6
8
10
12
14
16
18
Mean Gain VA from
Baseline
OPT-302 +
Lucentis®
(n=4)
MeangaininVisualAcuity
fromBaseline(#letters)
OPT-302 + Lucentis®
(n=4)
Week 12
0
100
200
300
400
500
600
Baseline
214 uM (42.7%)
Mean Central Subfield Thickness
MeanCST(uM)
11. 11
Combination Therapy: Prior-Treated Patients
• Mean number prior treatment injections: 10.5 (range 3 – 55)
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
Mean Change VA
from Baseline
Week 12
OPT-302 + Lucentis®
(n=10)
4 letters
MeangaininVisualAcuity
fromBaseline(#letters)
330
340
350
360
370
380
390
400
Mean Central Subfield
Thickness
OPT-302 + Lucentis®
(n=10)
Week 12Baseline
42 uM (11%)
MeanCST(uM)
14. OPT-302 Monotherapy
• 3/5 patients did not require ‘rescue’ therapy
• 2 patients were rescued (at d25 and d29). At week 12, both had lost vision compared
to baseline.
• At week 12, in patients that did not require rescue therapy, mean VA gain of 3.3
letters from baseline (range 2 to 6 letters) and mean increase in CST of 18 uM
Baseline Week 12
OPT-302 (2 mg)
Non Rescue pts (n=3)
250
275
300
325
350
375
400
MeanCST(uM)
Mean Central Subfield Thickness
+18µM
0
1
2
3
4
5
6
7
8
9
10
OPT-302 (2mg)
(n=5)
OPT-302 Non-
resue (2mg) (n=3)
Mean VA gain from
baseline at Week 12
0
1
2
3
4
5
6
7
8
9
10
OPT-302 (2 mg)
Non Rescue pts (n=3)
MeangaininVA
fromBaseline(#letters)
3 letters
15. • Large unmet medical need for wet AMD, current treatments only target VEGF-A
• OPT-302 targets VEGF-C and VEGF-D that are associated with incomplete response to
VEGF-A inhibition
• OPT-302 met primary objective of Phase 1 study: OPT-302 safe & well tolerated
• Evidence of clinical activity:
• Patients treated with combination OPT-302 + Lucentis® therapy showed mean
vision gains and retinal thickness improvements equal to or superior to historic, 12
week anti-VEGF-A (Lucentis®) alone, despite including heavily pre-treated, sub-
responsive patients with a high proportion of occult lesions
• Naïve pts: data suggests meaningful additional VA gain and reduction in CST with
OPT-302 + Lucentis® compared to historic data with Lucentis® alone
• Prior Tx pts: improved outcomes in difficult to treat, sub-responsive pts suggest
additional benefit of VEGF-A, VEGF-C and VEGF-D inhibition
• OPT-302 monotherapy maintained mean VA and CST
• Totality of data warrants advancing OPT-302 + Lucentis® to a Phase 2B randomised,
controlled trial
• Actively accruing into Phase 2A , planning for Phase 2B in 2017
15
OPT-302 Program Highlights
16. Suite 0403, Level 4,
650 Chapel Street,
South Yarra 3141 Victoria Australia
T +61 (0) 447 788 674
E megan.baldwin@opthea.com
www.opthea.com